Global Clinical Trials Market
- MAR2978588
- 179 Pages
- August 2018
- Pharmaceuticals
Market Dynamics
The factors that drive growth for the Clinical Trials Market include ever-increasing burden of diseases and their prevalence as well as the globalization of clinical trials. The pressures of regulatory guidelines are a major challenge for this industry. Another challenge for this industry is the high cost of conducting trials and associated research.
The market also throws up several opportunities with regard to the digitization of biomedical systems.
Market Segmentation
The market is segmented in terms of the phase, study design, indication, and geography.
In terms of the phase, the market is classified into phase 1, phase 2, phase 3 and phase 4. In phase 1 trials a small group of people is tested for a new treatment for their side effects and safety. In phase 2 trials frequent reviews are conducted to find the effectiveness of these. In phase 3 trials a large group of people is tested to confirm the effectiveness of treatment and further examine its side effects and for the comparison of new treatments with existing treatments.
In terms of study design, the market is segmented into Interventional, Observational and Expanded Access. The most popular method is the interventional clinical trials method.
In terms of indication, the market is divided into Oncology, CNS condition, Autoimmune, Pain management, Diabetes, Obesity.
The different geographic market segments are North America, Europe, Asia Pacific and Rest of the world.
Regional/Geographic Analysis
North America is the dominating market in terms of market share due to the increasing number of contract outsourcing firms, and the research & development in the region. North America is followed by Europe in terms of market share. But in terms of growth rate, Asia Pacific is the expected to be the leader because of the developing infrastructure.
Key Players
Some of the major players in the market include Charles River Laboratories, Quintiles IMS, and SGS SA.
The report contains comprehensive analysis on:
Global Clinical Trials Market Segments
Global Clinical Trials Market Drivers, Restraints and Opportunities
Global Clinical Trials Market Size & Forecast 2016 to 2022
Supply & Demand Value Chain
Global Clinical Trials Market Current Trends
Competition & Major Companies
Technology and R&D Status
Porters Five Force Analysis
Strategic and Critical Success Factor Analysis of Key Players
Regional analysis for Global Clinical Trials Market includes
--> North America
>> US and Canada
--> Latin America
>> Mexico, Brazil, Argentina and Rest of Latin America
--> Western Europe
>> EU5 (Germany, France, Italy, Spain, U.K.)
>> Nordic Countries (Denmark, Finland, Norway, and Sweden)
>> Benelux (Belgium, The Netherlands, and Luxembourg)
>> Rest of Western Europe
--> Eastern Europe
>> Russia
>> Poland
>> Rest of Eastern Europe
--> Asia Pacific
>> China
>> India
>> Japan
>> Australia and New Zealand
>> Rest of Asia Pacific
--> Middle East and Africa
>> GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
>> South Africa
>> North Africa
>> Rest of Middle East and Africa
This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides in-depth market segmentation that is derived from extensive product mapping exercises, macro-economic factors and other qualitative and quantitative insights. The impact of all such factors are delivered across multiple market segments and geographies.
Report Highlights::
--> Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
--> Consumer and Pricing Analysis
--> Market dynamics of the industry
--> In-depth Market Segmentation
--> Historical and Projected Market Sizing in terms of volume and value
--> Recent market trends and Impact Factors
--> R&D Status and Technology Overview
--> Extensive Industry Structure Coverage
1.1. Market Definition
1.2. Market Taxonomy
2. Research Methodology
3. Assumptions and Acronyms
4. Executive Summary
5. Historical Overview (Market Origins, Product Launch Timeline, etc.)
6. Pricing Analysis
7. Market Dynamics
7.1. Macroeconomic Factors
7.2. Drivers
7.2.1. Supply Side
7.2.2. Demand Side
7.3. Restraints
7.4. Opportunities
8. R&D Status and Technology Overview
9. Respiratory Clinical Trials Market Analysis
9.1. Introduction
9.2. Current Market Size and Growth (US$ Mn)
9.3. Key Stakeholders
9.3.1. Biotech and Pharmaceutical Companies
9.3.2. Academic and Research Institutions
9.3.3. Others
9.4. Service Providers - Types
9.4.1. External Assessment Agencies
9.4.1.1. Targeted Service Providers
9.4.1.2. Broad-based Service Providers
9.4.2. Database Management and Technical Support
9.4.3. Others
9.5. Chronic Respiratory Disorders - Commercial viability, Novelty and Perceived Value
9.5.1. COPD (Chronic obstructive pulmonary disease)
9.5.2. Asthma
9.5.3. Interstitial Lung Disease
9.5.4. Pulmonary Vascular Disease
9.5.5. Cystic Fibrosis
9.5.6. Chronic Pneumonia
9.5.7. Lung Cancer
9.5.8. Others
9.6. Use of External Vendors
9.6.1. Independent Assessment of Test Results
9.6.2. Provision of Spirometers and Other Machines
9.6.3. Technological Innovations – How App-based services can reduce human error and
introduce cost efficiency into current market
9.6.3.1. Addressing Oversight and Quality Issues in Spirometry Testing
9.6.3.2. Instrument Standardization – Role of Input variables and Accuracy
9.6.3.3. Technician Qualification and Supervision
9.6.3.4. Data Transmission and Management Issues
9.6.3.5. Disease Profile Variability – Impact of Genetic Factors, Smoking, Environment, etc.
10. Global Clinical Trials Market Analysis, By Service Type
10.1. Introduction
10.2. Market Size and Analysis, By Service Type
10.2.1. Research and Development
10.2.2. Preclinical
10.2.3. Clinical
10.2.3.1. Phase I
10.2.3.2. Phase II
10.2.3.3. Phase III
10.2.4. Post-Approval Consulting
10.2.5. Combination and Full Scale Providers
10.3. Market Share Analysis and YoY Growth Rates, By Service Type
11. Global Clinical Trials Market Analysis, By Therapeutic Area
11.1. Introduction
11.2. Market Size and Analysis, By Therapeutic Area
11.2.1. Cardiovascular
11.2.2. Diabetes, Endocrinology and Nephrology
11.2.3. Immuno-Oncology
11.2.4. Infectious Diseases
11.2.5. Inflammation
11.2.6. Neuroscience
11.2.7. Oncology
11.2.8. Rare Diseases Drug Developments
11.2.9. Pediatrics
11.2.10. Others
11.3. Market Share Analysis and YoY Growth Rates, By Therapeutic Area
12. Global Clinical Trials Market Analysis, By Region
12.1. Introduction
12.2. Market Size and Analysis, By Region
12.2.1. North America
12.2.2. Latin America
12.2.3. Europe
12.2.4. Asia Pacific
12.2.5. Middle East & Africa (MEA)
12.3. Market Share Analysis and YoY Growth Rates, By Region
13. North America Clinical Trials Market Analysis
13.1. Introduction
13.2. Prominent Trends
13.3. North America Clinical Trials Market Analysis, by Country
13.3.1. U.S.
13.3.2. Canada
13.4. North America Clinical Trials Market Analysis, By Service Type
13.4.1. Research and Development
13.4.2. Preclinical
13.4.3. Clinical
13.4.3.1. Phase I
13.4.3.2. Phase II
13.4.3.3. Phase III
13.4.4. Post-Approval Consulting
13.4.5. Combination and Full Scale Providers
13.5. North America Clinical Trials Market Analysis, By Therapeutic Area
13.5.1. Cardiovascular
13.5.2. Diabetes, Endocrinology and Nephrology
13.5.3. Immuno-Oncology
13.5.4. Infectious Diseases
13.5.5. Inflammation
13.5.6. Neuroscience
13.5.7. Oncology
13.5.8. Rare Diseases Drug Developments
13.5.9. Pediatrics
13.5.10. Others
13.6. North America Clinical Trials Market Share Analysis and YoY Growth Rates
13.6.1. By Country
13.6.2. By Service Type
13.6.3. By Therapeutic Area
14. Latin America Clinical Trials Market Analysis
14.1. Introduction
14.2. Prominent Trends
14.3. Latin America Clinical Trials Market Analysis, by Country
14.3.1. Mexico
14.3.2. Brazil
14.3.3. Others
14.4. Latin America Clinical Trials Market Analysis, By Service Type
14.4.1. Research and Development
14.4.2. Preclinical
14.4.3. Clinical
14.4.3.1. Phase I
14.4.3.2. Phase II
14.4.3.3. Phase III
14.4.4. Post-Approval Consulting
14.4.5. Combination and Full Scale Providers
14.5. Latin America Clinical Trials Market Analysis, By Therapeutic Area
14.5.1. Cardiovascular
14.5.2. Diabetes, Endocrinology and Nephrology
14.5.3. Immuno-Oncology
14.5.4. Infectious Diseases
14.5.5. Inflammation
14.5.6. Neuroscience
14.5.7. Oncology
14.5.8. Rare Diseases Drug Developments
14.5.9. Pediatrics
14.5.10. Others
14.6. Latin America Clinical Trials Market Share Analysis and YoY Growth Rates
14.6.1. By Country
14.6.2. By Service Type
14.6.3. By Therapeutic Area
15. Europe Clinical Trials Market Analysis
15.1. Introduction
15.2. Prominent Trends
15.3. Europe Clinical Trials Market Analysis, by Country
15.3.1. Germany
15.3.2. U.K.
15.3.3. Spain
15.3.4. France
15.3.5. Italy
15.3.6. Russia
15.3.7. Others
15.4. Europe Clinical Trials Market Analysis, By Service Type
15.4.1. Research and Development
15.4.2. Preclinical
15.4.3. Clinical
15.4.3.1. Phase I
15.4.3.2. Phase II
15.4.3.3. Phase III
15.4.4. Post-Approval Consulting
15.4.5. Combination and Full Scale Providers
15.5. Europe Clinical Trials Market Analysis, By Therapeutic Area
15.5.1. Cardiovascular
15.5.2. Diabetes, Endocrinology and Nephrology
15.5.3. Immuno-Oncology
15.5.4. Infectious Diseases
15.5.5. Inflammation
15.5.6. Neuroscience
15.5.7. Oncology
15.5.8. Rare Diseases Drug Developments
15.5.9. Pediatrics
15.5.10. Others
15.6. Europe Clinical Trials Market Share Analysis and YoY Growth Rates
15.6.1. By Country
15.6.2. By Service Type
15.6.3. By Therapeutic Area
16. Asia Pacific Clinical Trials Market Analysis
16.1. Introduction
16.2. Prominent Trends
16.3. Asia Pacific Clinical Trials Market Analysis, by Country
16.3.1. India
16.3.2. China
16.3.3. Australia & New Zealand
16.3.4. Japan
16.3.5. Others
16.4. Asia Pacific Clinical Trials Market Analysis, By Service Type
16.4.1. Research and Development
16.4.2. Preclinical
16.4.3. Clinical
16.4.3.1. Phase I
16.4.3.2. Phase II
16.4.3.3. Phase III
16.4.4. Post-Approval Consulting
16.4.5. Combination and Full Scale Providers
16.5. Asia Pacific Clinical Trials Market Analysis, By Therapeutic Area
16.5.1. Cardiovascular
16.5.2. Diabetes, Endocrinology and Nephrology
16.5.3. Immuno-Oncology
16.5.4. Infectious Diseases
16.5.5. Inflammation
16.5.6. Neuroscience
16.5.7. Oncology
16.5.8. Rare Diseases Drug Developments
16.5.9. Pediatrics
16.5.10. Others
16.6. Asia Pacific Clinical Trials Market Share Analysis and YoY Growth Rates
16.6.1. By Country
16.6.2. By Service Type
16.6.3. By Therapeutic Area
17. Middle East and Africa (MEA) Clinical Trials Market Analysis
17.1. Introduction
17.2. Prominent Trends
17.3. Middle East and Africa Clinical Trials Market Analysis, by Country
17.3.1. GCC countries
17.3.2. South Africa
17.3.3. North Africa
17.3.4. Rest of Middle East and Africa
17.4. Middle East and Africa Clinical Trials Market Analysis, By Service Type
17.4.1. Research and Development
17.4.2. Preclinical
17.4.3. Clinical
17.4.3.1. Phase I
17.4.3.2. Phase II
17.4.3.3. Phase III
17.4.4. Post-Approval Consulting
17.4.5. Combination and Full Scale Providers
17.5. Middle East and Africa Clinical Trials Market Analysis, By Therapeutic Area
17.5.1. Cardiovascular
17.5.2. Diabetes, Endocrinology and Nephrology
17.5.3. Immuno-Oncology
17.5.4. Infectious Diseases
17.5.5. Inflammation
17.5.6. Neuroscience
17.5.7. Oncology
17.5.8. Rare Diseases Drug Developments
17.5.9. Pediatrics
17.5.10. Others
17.6. Middle East and Africa Clinical Trials Market Share Analysis and YoY Growth Rates
17.6.1. By Country
17.6.2. By Service Type
17.6.3. By Therapeutic Area
18. Industry Structure
18.1. Porters Five Forces Analysis
18.1.1. Bargaining Power of Suppliers
18.1.2. Bargaining Power of Buyers
18.1.3. Threat of New Entrants
18.1.4. Threat of Substitute Products and Services
18.1.5. Internal Rivalry
18.2. Supply Chain Analysis and Profitability Margins
18.3. Market Share Analysis
18.4. Strategic Analysis
18.4.1. Competitive Strategies
18.4.2. Mergers & Acquisitions Activity
18.4.3. Co-operative Agreements
18.5. Critical Success Factor (CSF) Analysis (Technology & Manufacturing, Design & Features, Brand
Reputation, Distribution Network, Marketing)
18.6. Company Profiles (Overview, Product/Service Details, Geographic Scope, Financials, Strategic
Intent & Approach, Core Competencies & Competitive Advantage and Key developments)
18.6.1. Portable/Hand-held Spirometry Startups and Manufacturers
18.6.1.1. Cohero Health, Inc.
18.6.1.2. NuvoAir AB
18.6.1.3. VitalFlo
18.6.1.4. Spriosure, Inc.
18.6.1.5. Others
18.6.2. Major Contract Research Organizations
18.6.2.1. Laboratory Corporation of America Holdings (Covance)
18.6.2.2. IQVIA
18.6.2.3. Syneos Health
18.6.2.4. Parexel International Corp.
18.6.2.5. PRA Health Services Inc.
18.6.2.6. Pharmaceutical Product Development, LLC
18.6.2.7. Charles River Laboratories International, Inc.
18.6.2.8. Icon Public Limited Corp.
18.6.2.9. Wuxi Apptec
18.6.2.10. Medpace Holdings, Inc.
18.6.2.11. Others
18.6.3. Support and Other Technology Companies
19. Prognosis for the Future
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
